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Cell migration and metastasis formationTumor invasion and metastasis is a multi-step process
that requires adaptation of cancer cells to conditions
that they encounter during their journey to distant
body sites. Understanding the molecular processes
that underlie this adaptation is of exceeding impor-
tance because most cancer patients die because of
metastases rather than primary tumors. In this review
we assess genetically engineered mouse models
(GEMMs) that have been established to investigate
mechanisms of cancer invasion and metastasis.
Introduction
Tumor progression is associated with distinct histopatholo-
gical changes that are indicative for prognosis. Stromalization
and microvessel density increase during tumor progression
and tumor cells establish heterotypic molecular interactions
with stromal cells that support invasiveness. The acquired
ability of tumor cells to locally invade adjacent tissues is the
first important step in the invasion-metastasis cascade [1].
Two general strategies have been pursued in mice to inves-
tigate invasive tumor progression. The first strategy uses
genetically engineered mouse models (GEMMs) that are sui-
table for the investigation of early steps in cancer invasion but
infrequently give rise to far distant metastases. The second
strategy uses transplantation of tumor cells or tumor tissue
into host mice and is employed to study early invasiveness*Corresponding author: R. Eferl (robert.eferl@lbicr.lbg.ac.at)
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but also later stages such as intravasation, extravasation and
colonization of tumor cells [2]. Here, we focus on GEMMs for
major malignancies in humans and the progress that has
been made to model human metastasis.
GEMMs as models for cancer invasion and metastasis
Tumors that appear in GEMMs as a result of the correspond-
ing genetic manipulation often show a low incidence to
develop far distant metastasis. This is also true for deletions
of tumor suppressor genes that are associated with a high
metastatic potential in human cancers. The long latency
period makes it difficult to predict the onset of metastasis
which impedes monitoring in mice despite the availability
of advanced in vivo imaging techniques. Therefore, many
researchers favor the use of transplantation models to study
metastasis although they might neglect the impact of the
immune system or skip important initial steps in the meta-
static cascade such as local tissue invasion or intravasation
[1,2]. However, several recently established GEMMs might
represent promising new tools to investigate invasive pro-
cesses and metastasis in certain cancer types (Table 1).
Invasive and metastasizing breast cancer models
Human breast cancer frequently metastasizes to liver, bone,
lung and brain. To model breast cancer in mice, potentialod.2011.05.003 67
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Table 1. GEMMs that display invasive and metastasizing tumors (list is not complete). %: percent of mice with metastases; LN:
lymph nodes; GI: gastrointestinal tract; pan.: pancreas; kid.: kidney; AG: adrenal gland; epid.: epididymis; ov.: ovary
Mouse model Tumor Metastasis % Refs Weblink
MMTV-rtTA/TetO-NeuNT Breast Lung 92 Moody (2002) [5] http://www.ncbi.nlm.nih.gov/pubmed/12498714
MMTV-ErbB2/
MMTV-Cre/PTENflox/flox
Breast Lung 87.5 Schade (2009) [37] http://www.ncbi.nlm.nih.gov/pubmed/19435886
MMTV-PyMT Breast LN, lung 80–100 Maglione (2001) [4] http://www.ncbi.nlm.nih.gov/pubmed/11719463
Wap-Cre/Cdh1flox/flox/
Trp53flox/flox
Breast LN, skin, lung,
liver, GI,
pan., spleen,
bone
70 Derksen (2011) http://www.ncbi.nlm.nih.gov/pubmed/21282721
MMTV-LMW-Cyl-E/
Trp53+/
Breast LN, lung, head 35.2 Akli (2007) http://www.ncbi.nlm.nih.gov/pubmed/17671189
MMTV-NeuN Breast Lung 11–72 Guy (1992) http://www.ncbi.nlm.nih.gov/pubmed/1359541
MT-Met Breast LN, lung, kid.,
heart, cecum
– Jeffers (1998) http://www.ncbi.nlm.nih.gov/pubmed/9826715
MMTV-Wnt1 Breast LN, lung – Li (2000) http://www.ncbi.nlm.nih.gov/pubmed/10713683
PB-Cre/PTENflox/flox/
Smad4flox/flox
Prostate LN, Lung 100 Ding (2011) [17] http://www.ncbi.nlm.nih.gov/pubmed/21289624
Cryptdin-2-Tag Prostate LN, lung, liver,
bone
85 Garabedian
(1998) [12]
http://www.ncbi.nlm.nih.gov/pubmed/9860977
PB-SV40T/t Prostate LN, lung 67–100 Gingrich (1996) [38] http://www.ncbi.nlm.nih.gov/pubmed/8797572
PB-Cre/PTENflox/flox Prostate LN, lung 45 Wang (2003) [13] http://www.ncbi.nlm.nih.gov/pubmed/14522255
Adeno-Cre/KRASG12D/
Apcflox/flox
Colon Liver 20 Hung (2010) [26] http://www.ncbi.nlm.nih.gov/pubmed/20080688
Adeno-Cre/KRASG12D/
LKB1flox/flox
Lung LN, skeleton 61 Ji (2007) [32] http://www.ncbi.nlm.nih.gov/pubmed/17676035
Adeno-Cre/KRASG12D/
Trp53flox/flox
Lung LN, distant organs 50 Jackson (2005) [39] http://www.ncbi.nlm.nih.gov/pubmed/16288016
SP-C-c-Raf/SP-C-c-Myc Lung LN, liver 24 Rapp (2009) [29] http://www.ncbi.nlm.nih.gov/pubmed/19551151
Adeno-Cre/KRASG12D/
INK4a/
Lung LN 20 Ji (2007) [32] http://www.ncbi.nlm.nih.gov/pubmed/17676035
SP-C-c-Myc Lung LN, liver 17 Rapp (2009) [29] http://www.ncbi.nlm.nih.gov/pubmed/19551151
Pdx1-Cre/KRASG12D/
Trp53R172H
Pancreas Liver, lung, LN,
diaphragm, AG
80 Hingorani
(2005) [40]
http://www.ncbi.nlm.nih.gov/pubmed/15894267
Rip-VEGF-C-Tag Pancreas LN 37 Mandriota (2001) http://www.ncbi.nlm.nih.gov/pubmed/11179212
Tyr-Cre/BRAFV600E/
PTENflox/flox
Melanoma LN, lung 100 Dankort (2009) http://www.ncbi.nlm.nih.gov/pubmed/19282848
MT-HGF/SF Melanoma Liver, lung,
pan., LN, epid.,
spleen, femur
21 Otsuka (1998) http://www.ncbi.nlm.nih.gov/pubmed/9823327
K14-PKC Skin LN 30 Jansen (2001) http://www.ncbi.nlm.nih.gov/pubmed/11221859
TRbPV/PV/PTEN+/ Thyroid Lung 80 Guigon (2009) http://www.ncbi.nlm.nih.gov/pubmed/18997818
TRa1//TRb/ Thyroid Lung 21 Zhu (2010) http://www.ncbi.nlm.nih.gov/pubmed/20062085
Adeno-Cre/Trp53flox/flox/
PTENflox/flox
Bladder LN, spleen, liver,
diaphragm
60 Puzio-Kuter
(2009)
http://www.ncbi.nlm.nih.gov/pubmed/19261747
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Table 1 (Continued )
Mouse model Tumor Metastasis % Refs Weblink
CK19-Tag Bladder Lung 20 Grippo (2000) http://www.ncbi.nlm.nih.gov/pubmed/10980120
Osx1-GFP-Cre/
Trp53flox/flox/Rbflox/flox
Osteosarcoma Lung, liver, AG,
spleen, kid., ov.
40 Berman (2008) http://www.ncbi.nlm.nih.gov/pubmed/18697945
AT-III-Tag Liver Lung 10 Dubois (1991) http://www.ncbi.nlm.nih.gov/pubmed/1660504
a-Amylase-Tag Adipose Liver, lung, AG,
spleen, heart
– Fox (1989) http://www.ncbi.nlm.nih.gov/pubmed/2785714oncogenes such as ErbB2, PyMT, Wnt1 and RAS have been
expressed in mammary epithelial cells under control of the
mammary gland-specific promoters MMTV and WAP (whey
acidic protein). Corresponding mouse models developed
breast cancers that frequently metastasized to the lung and
the lymph nodes [3]. In particular, MMTV-PyMT mice dis-
played efficient formation of metastases with a short latency
period (Fig. 1) [4]. The MMTV-PyMT transgene has been used
as driver oncogene for breast cancer development in various
knock-out mouse models which has revealed important gene
co-operativities during breast cancer metastasis. Combined
MMTV-PyMT/Akt1/ mice showed delayed onset of breast
cancer formation and compromised metastasis when com-
pared to MMTV-PyMT mice demonstrating the importance of
PI3K/Akt signaling [3]. Ablation of tumor-associated macro-
phages (TAMs) in MMTV-PyMT/Csf-1/ mice had no sub-
stantial effect on tumor growth but severely compromised
breast cancer invasiveness and lung metastasis [3]. Interest-
ingly, TAMs in MMTV-PyMT mice but not tumor cells
expressed epidermal growth factor (EGF). By contrast, the
EGF receptor was expressed by tumor cells but not TAMs. This
indicates that TAMs secrete EGF that acts on tumor cells
thereby establishing a heterotypic interaction that supports
invasiveness. Secretion of EGF by TAMs is stimulated by CD4+
T-cells as has been demonstrated by T-cell ablation in MMTV-
PyMT/Rag1/ and MMTV-PyMT/IL-4/ mice [3]. These
results suggest a heterotypic signaling network between
innate immune cells, adaptive immune cells and tumor cells
in breast cancer invasion. In addition to mammary gland-
specific constitutive expression of oncogenes, doxycycline-
inducible expression of TetO-NeuNT and TetO-c-Myc trans-
genes has been employed for the establishment of mouse
models with invasive breast cancer [3]. Of these models,
MMTV-rtTA/TetO-NeuNT mice developed metastasizing
breast cancer with high frequency [5]. Mouse models with
conditional deletion of important tumor suppressor genes in
mammary epithelial cells have also been used successfully for
modeling metastatic breast cancer. MMTV-Cre/Trp53flox/flox
mice developed breast tumors that efficiently metastasized to
lung and liver albeit after a long latency period (Fig. 1) [6]. The
latency period for primary tumor formation was shorter in
MMTV-Cre/Brca1flox/flox/Trp53+/ mice and metastases weredetected in lymph nodes and lung (Fig. 1) [7]. No efficient
bone metastasis has been reported in breast cancer mouse
models.
Invasive and metastasizing prostate cancer models
The primary target organ of human prostate cancer metas-
tases is the bone. Several prostate cancer mouse models have
been established that progress beyond the stage of prostatic
intraepithelial neoplasia (PIN) and display metastasis. These
models are based on conditional deletion of tumor suppressor
genes in the prostatic epithelium or on epithelial-specific
expression of oncogenes. In most cases, the rat probasin
(PB) promoter was used for Cre recombinase or oncogene
expression. To increase tissue specificity, a composite ARR2PB
promoter was developed that contains two androgen respon-
sive regions [8,9]. The TRAMP model for prostatic adenocar-
cinomas is based on PB promoter driven expression of SV40T/
t in the prostatic epithelium and developed metastases in the
lung and lymph nodes. Rarely, metastases in the bone, kidney
and adrenal glands were observed in TRAMP mice [8,9]. Less
aggressive prostatic carcinomas developed in the LADY
mouse model that is similar to TRAMP but lacks expression
of the SV40 small t antigen (therefore, LADY mice still display
protein phosphatase 2A activity). Prostatic tumors in LADY
mice were invasive and expressed neuroendocrine markers (a
subtype of human prostate cancer develops from neuroendo-
crine cells) but did not metastasize [8,9]. However, additional
expression of the serine protease hepsin which is highly
expressed in human prostate cancer under control of the
PB promoter conferred metastasis [10]. As an alternative
approach, the gene for SV40T was knocked into the PSP94
(prostate secretory protein 94) genomic locus that is highly
expressed in the prostate. Resulting PSP-KIMAP mice devel-
oped PINs and invasive carcinomas that metastasized to the
lymph nodes, lung and liver [11]. In addition to SV40 anti-
gens, Her-2/Neu and c-Myc was ectopically expressed in PB-
Her-2/Neu, PB-c-Myc and ARR2PB-c-Myc transgenic mice
which resulted in PINs and invasive adenocarcinomas. PB-
c-Myc mice developed invasive adenocarcinomas later than
ARR2PB-c-Myc which was attributed to a lower level of trans-
genic c-Myc expression [8,9]. To establish a model for neu-
roendocrine prostate cancer, the Cryptdin-2 promoter haswww.drugdiscoverytoday.com 69
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Figure 1. Mouse models (GEMMs) with efficient invasion and metastasis rates. The route of metastasis from primary organs (here shown as mouse
organs) to distant sites is indicated by arrows. Major target organs for human metastases and corresponding GEMMs that model the human tropisms are
shown. Strong arrows: most frequent sites for metastasis; weak arrows: less frequent sites for metastasis; interrupted arrows: currently no suitable mouse
model available.been used to express SV40T in neuroendocrine cells of the
prostate. The resulting prostatic tumor model developed
invasive carcinomas that expressed neuroendocrine markers
and metastasized predominantly to lymph nodes and liver
(infrequently also to lung and bone) [12].
Conditional deletion of tumor suppressor genes in the
prostate epithelium was mainly achieved with ARR2PB-Cre
transgenic mice. Deletion of PTEN, a tumor suppressor gene
that is frequently mutated in human prostate cancer, resulted70 www.drugdiscoverytoday.comin invasive carcinomas that metastasized to lymph nodes and
lung in 45% of mice [13]. Unfortunately, no metastasis to the
bone was observed indicating that the tropism of metastasis-
ing prostate cancer in this model differs from human prostate
cancer. In contrast to PTEN, conditional PB-Cre-mediated
deletion of Apc in the prostate resulted in invasive adeno-
carcinomas but no metastasis was observed [8,9]. Among
compound mouse models, PTEN+//Nkx3.1/ mice devel-
oped fewer PINs than Nkx3.1-proficient PTEN+/ mice that,
Vol. 8, No. 2–3 2011 Drug Discovery Today: Disease Models | Cell migration and metastasis formationhowever, progressed to invasive prostate cancer with lymph
node metastases beyond one year of age [14]. Moreover,
prostate-specific expression of Fgf8b in PTEN+/mice resulted
in adenocarcinoma formation by nine months of age that led
to lymph node metastases [15]. Conditional inactivation
of Trp53 and Rb in the prostatic epithelium resulted in
prostatic adenocarcinoma formation and metastasis to
lymph nodes, liver and lung [16]. Recently, compound
ARR2PB-Cre/PTEN
flox/flox/SMAD4flox/flox mice with condi-
tional deletion of PTEN and SMAD4 in the prostatic epithe-
lium have been generated. These mice represent a model for
invasive prostate cancer that metastasizes with 100% pene-
trance to lymph nodes and lung. Moreover, this model has
demonstrated that TGFb/SMAD4 signaling imposes a barrier
against prostate cancer metastasis. Unfortunately, no effi-
cient bone metastasis has been observed in this model [17].
Invasive and metastasizing colorectal cancer models
Human colorectal tumors predominantly metastasize to the
liver. Several genetic and chemical mouse models have been
employed to investigate intestinal cancer formation and
progression. The most frequently used chemical model for
the induction of colorectal tumors is the AOM/DSS model
which is based on a single injection of the carcinogen AOM
followed by repeated treatment of mice with Dextransulfate
(DSS) in the drinking water [18]. The most commonly used
genetic models exploit the strong tumor-inducing potential
of Apc mutations (ApcMin, ApcD716, Apc1638N) upon loss of
heterozygosity (LOH). These mouse models develop tumors
preferentially in the small intestine but not readily in the
colon [19]. Conditional inactivation of a floxed Apc allele has
been alternatively employed to induce intestinal tumors.
Although AOM/DSS treatment or mutation of Apc can lead
to the formation of invasive carcinomas at certain frequen-
cies, metastases have not been observed in these models.
Invasiveness and tumor progression were enhanced by
AOM/DSS treatment or introduction of additional mutations
in compound mouse models. AOM/DSS treated CEACAM1/
 mice (CEACAM1 is a cell adhesion molecule that is down-
regulated in human colorectal carcinomas) develop a higher
percentage of colorectal carcinomas that invade the muscu-
laris mucosa than corresponding control animals [20]. Simi-
larly, compound Apc1638N/CEACAM1/, ApcMin/PTEN+/
and ApcMin/SMAD3/mice were prone to the development
of invasive carcinomas which highlights the importance of
these pathways in intestinal cancer progression [21–23]. We
have demonstrated that conditional deletion of Stat3 in
intestinal epithelial cells (using the Villin-Cre transgene) of
ApcMin mice promotes invasiveness and nuclear localization
of b-Catenin via a CEACAM1-dependent mechanism [24].
However, no liver metastases have been detected in these
models which is most likely due to premature lethality of
tumor bearing mice. Evidence for liver metastases has beenobtained in compound Apc1638N/pVillin-KRASG12V mice.
Although metastases have not been observed histopatholo-
gically in the liver, tumor-specific pVillin-KRASG12V trans-
gene expression was detected in liver tissue of a subset of
tumor bearing mice indicating the presence of disseminated
tumor cells or micrometastases [25]. More recently, a stochas-
tic model for sporadic colorectal cancer has been established
that gives rise to Cdx-2+ liver metastases with considerable
efficiency [26]. This model is based on Adeno-Cre injection
into the colon of LSL-KRASG12V/Apcflox/flox mice (Fig. 1).
Adeno-Cre treatment deleted the floxed Apc alleles and the
loxP-stop-loxP cassette in front of the oncogenic KRASG12V
gene with low frequency in crypt stem cells. This protocol
avoids development of colorectal tumors at high numbers
therefore preventing premature lethality and allowing tumor
progression and metastasis.
Invasive and metastasizing lung cancer models
Human lung cancer often metastasizes to liver, bone and brain
whereas most mouse models develop adenomas or less fre-
quently adenocarcinomas that infrequently metastasize [27].
However, a recently reported lung cancer mouse model devel-
oped liver metastases that could be backtraced to the primary
tumors [28]. Transgenic approaches have used the surfactant
protein C (SP-C) and Clara cell secretory protein (CCSP) pro-
moters for oncogene or Cre recombinase expression in type II
pneumocytes or non-ciliated secretory Clara cells, respectively.
Expression of SV40T, c-Raf or c-Myc under control of these
promoters resulted in aggressive adenocarcinomas [27]. Metas-
tases were observed in SP-C-c-Myc single transgenic mice at
lower frequency but combined expression of SP-C-c-Myc and
SP-C-c-Raf in a compound double-transgenic mouse model
promoted formation of metastases [29]. Other approaches used
these promoters in the context of the ‘Tet-on’ system for
inducible transgene expression. CCSP-rtTA/TetO7-KRAS
G12D,
CCSP-rtTA/TetO7-BRAF
V600E and CCSP-rtTA/TetO7-PIK3-
CAH1047R mice developed adenocarcinomas after doxycycline
treatment. Lung tumor formation and progression in the first
two models was accelerated in a Trp53- or INK4a-negative
genetic background but no metastasis was observed [27]. In
addition to oncogenic KRAS, BRAF and PIK3CA (encoding
p110a of PI3K) alleles, different variants of EGF receptor ori-
ginally identified in human lung cancers have been inducibly
expressed. CCSP-rtTA/TetO7-EGFR
DEL, CCSP-rtTA/TetO7-
EGFRL858R and CCSP-rtTA/TetO7-EGFR
vIII mice developed
invasive adenocarcinomas but no metastases after doxycycline
application [27]. Knock-in approaches were used as alternative
to transgenic mice. Knock-in of the Trp53R270H allele that was
identified in Li-Fraumeni patients into the endogenous Trp53
locus gave rise to aggressive lung adenocarcinomas that even
metastasized (such tumors were not found in Trp53/ mice)
[30]. The most frequently used mouse model for inducible lung
cancer development is the LSL-KRASG12Dmodel that harbourswww.drugdiscoverytoday.com 71
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stop-loxP cassette. Cre induction using a Cre-transgenic mouse
or a viral infection protocol with Adeno-Cre particles leads to
deletion of the floxed stop cassette followed by KRASG12D
expression and formation of lung adenocarcinomas [31].
LSL-KRASG12D was crossed with CCSP-Cre/PTENflox/flox mice
leading to combined activation of RAS and PI3K signaling that
resulted in the formation of advanced vascularized adenocar-
cinomas but not metastasis [27]. Instead of PTEN, deletion of
tumor suppressor proteins LKB1, INK4a or Trp53 in LSL-
KRASG12D led to the formation of metastasizing lung adeno-
carcinomas (Fig. 1) [27]. Interestingly, LSL-KRASG12D/LKB1flox/
flox mice developed not only adenocarcinomas but also squa-
mous cell carcinomas and large cell carcinomas upon treat-
ment with Adeno-Cre particles [32]. Metastases in the lymph
nodes (61% of mice) and axial skeleton (9% of mice) were
observed in this model. Recently, a LSL-KRASG12D/Trp53flox/flox
lung cancer model has been reported where tumor formation
was induced by lentiviral delivery of Cre (Lenti-Cre) to the
lung. These mice developed metastases to lymph nodes,
pleura, kidney, heart, adrenal glands and liver with high
frequency (Fig. 1). Because Lenti-Cre integrates randomly into
the genome, the integration site was used as a unique mole-
cular identifier to link primary tumors with related metastases
which allowed the identification of metastasis-regulating
genes [28].
Invasive and metastasizing pancreatic cancer models
Pancreatic cancer in humans is a very aggressive malignant
disease with rapid formation of metastases in the liver. The
classical mouse model for pancreatic carcinoma is the Rip-Tag
model that expresses the SV40T oncogene under control of
the rat insulin promoter [33]. This model was very instructive
for the investigation of tumor progression, angiogenesis and
metastasis and was also used in different drug treatment
protocols. However, the most frequent type of pancreatic
cancer is represented by pancreatic ductular adenocarcinomaTable 2. Advantages and disadvantages of GEMMs and transplan
reference [2])
GEMMs Allogra
Pros Immunocompetent environment Immuno
Tumors in original tissues Wide ra
Cre-mediated genetic manipulation of stroma/tumor cells Timely w
Defined genetic background Short la
Cons Extensive genetic manipulation in mice Limited 
Metastatic tropism often different from human tumors Non-hum
Timely not well defined onset of metastasis 
Long latency
Non-human system
72 www.drugdiscoverytoday.com(PDAC) and not islet carcinomas that develop in Rip-Tag
mice. Similar to lung adenocarcinoma models, most models
for PDAC rely on LSL-KRASG12D mice [31]. Deletion of the
loxP-stop-loxP cassette was performed with Pdx1-Cre and
p48-Cre transgenic mice which was sufficient for the for-
mation of invasive and metastatic PDAC albeit at low
frequency [34]. Preferential sites of metastasis in these
models were lymph nodes, liver, lung, pleura and the neural
plexus [35]. Compound Pdx1-Cre/LSL-KRASG12D or p48-
Cre/LSL-KRASG12D mice with additional deletion of tumor
suppressors INK4a, Trp53, SMAD4 and TGFbRII developed
invasive PDAC that metastasized to many organs (Fig. 1)
[34]. Moreover, knock-in of KRASG12D into the Mist1 locus
(Mist1tmKRASG12D mice) that is expressed during pancreas
development resulted in invasive and metastatic pancreatic
cancers of different histopathologic appearance. Tumor
progression and formation of liver metastasis were pro-
moted in Mist1tmKRASG12D Trp53+/ mice [36] confirming
cooperativity between KRAS and loss of Trp53 (Fig. 1).
Pancreatic cancer models that are based on inducible Cre
activity are EL-tTA/TRE-Cre/LSL-KRASG12V and EL-CreERT/
cLGL-KRAS mice that develop invasive and invasive/meta-
static PDAC, respectively [34].
Comparison and further development of metastatic
mouse models
The value of GEMMs as mouse models for invasion and
metastasis of cancers is influenced by several parameters that
include the human relevance of introduced genetic changes
to get metastasizing tumors, penetrance of metastasis and
target organs of metastasizing cells. Still, some GEMMs do not
satisfactorily model human metastasis and for preclinical
studies, evaluation of the drug response of human cancer
cells in xenograft models might be required (Table 2). How-
ever, metastasis-associated gene expression patterns obtained
from human tumor samples or via in vivo selection of organ-
specific metastatic tumor cell lines might be used to introducetation systems for investigation of metastasis (for review see
fts Xenografts
competent environment Use of human tumor cells
nge of metastatic target organs Range of orthologous metastatic tropism
ell defined onset of metastasis Timely well defined onset of metastasis
tency Usually short latency
number of suitable cell lines Immunodeficient environment
an system Non-responsiveness of tumor cells to
some host factors (e.g. mouse IL-6)
Altered behavior of human tumor
cells at high passages
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rates in compound GEMMs. The complexity of tumor metas-
tasis could, however, require a further refinement of experi-
mental tools in mouse models (e.g. the application of
different recombination systems to get sequential activation
or deletion of genes relevant for metastasis).
GEMMs and human metastatic disease
GEMMs have been established to understand the major
mechanisms underlying invasion and metastasis in humans
and for the evaluation of antimetastatic drug treatments.
Major drawbacks are imposed by the pharmacokinetics of
drugs that are not applicable to humans and the differential
tropism of mouse and human tumors. Moreover, most mouse
models for invasive and metastasizing cancer rely on expres-
sion or deletion of the ‘usual suspects’ of oncogenes and
tumor suppressor genes. Human cancers also rely on these
genes but metastasis might be more complex and affected by
additional pathways that are not yet taken into account in
available mouse models.
Conclusions
Syngeneic and xenograft models using human cancer cells
transplanted into host mice might still provide the method of
choice to investigate far distant metastasis or to apply drug
treatments. At present, GEMMs are more commonly used for
the investigation of tumor initiation or local invasiveness
because metastasis occurs infrequently or is restricted to lymph
nodes and lung. However, recently established mouse models
for metastasizing prostate and lung cancer nourish the hope
that GEMMs with comparable metastasis rates and tropisms to
human cancers will be developed which are of preclinical
relevance.
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